| abstract |
The present application is a formulation comprising or consisting of a binding moiety having specificity to kallikrein protein (eg, PSA or hK2) used for the treatment of prostate cancer, and a formulation comprising or consisting of a binding moiety having specificity to kallikrein protein It provides a method of treating prostate cancer in a patient, comprising administering to the patient a therapeutically effective amount of. |